[go: up one dir, main page]

WO1992000011A3 - Antagonistes de leukotriene b?4¿ - Google Patents

Antagonistes de leukotriene b?4¿ Download PDF

Info

Publication number
WO1992000011A3
WO1992000011A3 PCT/US1991/004386 US9104386W WO9200011A3 WO 1992000011 A3 WO1992000011 A3 WO 1992000011A3 US 9104386 W US9104386 W US 9104386W WO 9200011 A3 WO9200011 A3 WO 9200011A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
leukotriene
antagonists
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/004386
Other languages
English (en)
Other versions
WO1992000011A2 (fr
Inventor
Stevan Wakefield Djuric
Stephen Hermann Docter
Stella Siu-Tzyy Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to DE69115297T priority Critical patent/DE69115297T2/de
Priority to JP3515594A priority patent/JP2942630B2/ja
Priority to EP91916271A priority patent/EP0593478B1/fr
Priority to CA002081766A priority patent/CA2081766C/fr
Publication of WO1992000011A2 publication Critical patent/WO1992000011A2/fr
Publication of WO1992000011A3 publication Critical patent/WO1992000011A3/fr
Priority to US07/995,859 priority patent/US5310951A/en
Anticipated expiration legal-status Critical
Priority to GR950403300T priority patent/GR3018322T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Spray-Type Burners (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention se rapporte à des composés de formule (I) et aux stéréoisomères et aux sels pharmaceutiquement acceptables de ces composés où R représente alkyle, alcényle, alkynyle ou cycloalkylalkyle; R1 représente alkyle; R2 représente hydrogène ou alkyle; R6 représente alkyle; n représente de 1 à 5; p représente de 0 à 6; x représente 0 ou 2; et R4 et R5 sont indépendamment hydrogène ou alkyle ou forment avec N une cycloalkylamine. Les composés de formule (I) sont des antagonistes de leukotriène B4 et sont utiles comme agents anti-inflammatoires et dans le traitement de maladies où agit le LTB4.
PCT/US1991/004386 1990-06-28 1991-06-27 Antagonistes de leukotriene b?4¿ Ceased WO1992000011A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69115297T DE69115297T2 (de) 1990-06-28 1991-06-27 Leukotrien-b4-antagonisten.
JP3515594A JP2942630B2 (ja) 1990-06-28 1991-06-27 ロイコトリエンｂ▲下４▼アンタゴニスト
EP91916271A EP0593478B1 (fr) 1990-06-28 1991-06-27 Antagonistes de leukotriene b 4
CA002081766A CA2081766C (fr) 1990-06-28 1991-06-27 Antagonistes du leucotriene b4
US07/995,859 US5310951A (en) 1990-06-28 1992-12-23 Leukotriene B4 antagonists
GR950403300T GR3018322T3 (en) 1990-06-28 1995-12-07 Leukotriene b 4 antagonists.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/545,430 US5124350A (en) 1990-06-28 1990-06-28 Leukotriene b4 antagonists
US545,430 1990-06-28

Publications (2)

Publication Number Publication Date
WO1992000011A2 WO1992000011A2 (fr) 1992-01-09
WO1992000011A3 true WO1992000011A3 (fr) 1992-02-06

Family

ID=24176217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004386 Ceased WO1992000011A2 (fr) 1990-06-28 1991-06-27 Antagonistes de leukotriene b?4¿

Country Status (13)

Country Link
US (4) US5124350A (fr)
EP (1) EP0593478B1 (fr)
JP (1) JP2942630B2 (fr)
AT (1) ATE131165T1 (fr)
AU (1) AU8528291A (fr)
CA (1) CA2081766C (fr)
DE (1) DE69115297T2 (fr)
DK (1) DK0593478T3 (fr)
ES (1) ES2080334T3 (fr)
GR (1) GR3018322T3 (fr)
IE (1) IE62680B1 (fr)
PT (1) PT98140B (fr)
WO (1) WO1992000011A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5488160A (en) * 1991-06-11 1996-01-30 Ciba-Geigy Corporation Amidino compounds, their manufacture and method of treatment
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5516917A (en) * 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
NZ285154A (en) * 1994-10-13 1998-11-25 Pfizer Optionally heterocyclically substituted benzopyran and benzo-fused derivatives, preparation and use as leukotriene antagonists
CN1160399A (zh) * 1994-10-13 1997-09-24 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
JPH11507669A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
EP0880362B1 (fr) * 1996-02-13 2005-05-25 G.D. SEARLE & CO. Compositions renfermant un inhibiteur de cyclooxygenase-2 et un antagoniste de recepteur de leucotriene b 4
US6403684B1 (en) * 1998-12-16 2002-06-11 General Electric Company Polyetherimide resin/polyester resin blends having improved visual clarity
CA2423141A1 (fr) 2000-09-27 2002-04-04 Merck & Co., Inc. Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques
AU2002248221B2 (en) 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2008506768A (ja) * 2004-07-22 2008-03-06 ファルマシア コーポレーション Ｃｏｘ−２選択的阻害剤とｌｔｂ４受容体アンタゴニストを組み合わせて用いる炎症および疼痛を治療するための組成物
US7572600B2 (en) * 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
SI1877379T1 (sl) * 2005-04-13 2013-05-31 Astex Therapeutics Limited Derivati hidroksibenzinamida in njih uporaba kot inhibitorji HSP90
US7754725B2 (en) * 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
JP5528807B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044029A1 (fr) * 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2073804B1 (fr) 2006-10-12 2017-09-13 Astex Therapeutics Limited Composes amides d'acide benzoique substitues par un groupe hydroxyle pour son utilisation dans le traitement de la douleur
US8779132B2 (en) * 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044041A1 (fr) * 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
GB0806527D0 (en) * 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (fr) * 1979-09-05 1981-05-06 Glaxo Group Limited Dérivés de phénol, procédés pour leur préparation et composés pharmaceutiques les contenant
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
EP0336068A1 (fr) * 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Dérivés de phénoxyalkoxy-3,4-dihydro-2H-1-benzopyrane
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1384530A (en) * 1971-07-29 1975-02-19 Fisons Ltd Chromone derivatives
ATE14579T1 (de) * 1979-03-20 1985-08-15 Fisons Plc Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
ATE25251T1 (de) * 1981-11-12 1987-02-15 Fisons Plc Anti srs-a carbonsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische formulierungen.
ZA844519B (en) * 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4778903A (en) * 1983-12-12 1988-10-18 G. D. Searle & Co. Substituted dihydrobenzopyrans
US4665203A (en) * 1983-08-08 1987-05-12 G. D. Searle & Co. Substituted dihydrobenzopyrans useful as leukotriene D4 inhibitors
US4546194A (en) * 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
DE4206523A1 (de) * 1992-03-02 1993-09-09 Vdo Schindling Vorrichtung zur verstellung einer drosselklappe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (fr) * 1979-09-05 1981-05-06 Glaxo Group Limited Dérivés de phénol, procédés pour leur préparation et composés pharmaceutiques les contenant
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
EP0336068A1 (fr) * 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Dérivés de phénoxyalkoxy-3,4-dihydro-2H-1-benzopyrane

Also Published As

Publication number Publication date
US5310951A (en) 1994-05-10
IE912255A1 (en) 1992-01-01
CA2081766A1 (fr) 1991-12-29
ES2080334T3 (es) 1996-02-01
US5532383A (en) 1996-07-02
PT98140A (pt) 1993-09-30
US5124350A (en) 1992-06-23
DE69115297D1 (de) 1996-01-18
US5439937A (en) 1995-08-08
GR3018322T3 (en) 1996-03-31
AU8528291A (en) 1992-01-23
CA2081766C (fr) 2002-10-08
DK0593478T3 (da) 1996-01-08
JPH05507720A (ja) 1993-11-04
EP0593478A1 (fr) 1994-04-27
IE62680B1 (en) 1995-02-22
WO1992000011A2 (fr) 1992-01-09
ATE131165T1 (de) 1995-12-15
DE69115297T2 (de) 1996-06-13
PT98140B (pt) 1998-12-31
JP2942630B2 (ja) 1999-08-30
EP0593478B1 (fr) 1995-12-06

Similar Documents

Publication Publication Date Title
WO1992000011A3 (fr) Antagonistes de leukotriene b?4¿
IE830479L (en) Carboxyalkyl dipeptides
DE3176029D1 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
ZA916579B (en) Heterocyclic compounds and their preparation and use
GR3020715T3 (en) Xanthine compounds
GR3018479T3 (en) Heterocyclic compounds and their preparation and use.
DE69428665D1 (de) Hemmung von CNS-Problemen bei Frauen nach der Menopause
CA2449679A1 (fr) Androstenones
GR3007401T3 (fr)
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
CA2056793A1 (fr) 5-amino-5,6,7,8-tetrahydroquinoleines et composes apparentes; methode de preparation et utilisation comme medicaments
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
AU7892591A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
EP0274230A3 (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
EP0370821A3 (fr) Dérivés de 1,4-dihydropyridine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2081766

Country of ref document: CA

Ref document number: 1991916271

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1991916271

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991916271

Country of ref document: EP